Myelodysplastic Syndrome
Conditions
Brief summary
This is an extension study to investigate long term safety and efficacy of SyB C-1101 when orally administered every 3 weeks, twice daily for 14 consecutive days to the patients who have completed 6 cycles in the study 2012002 whose purpose is to investigate tolerability of SyB C-1101 when administered orally in patients with recurrent/relapsed or refractory myelodysplastic syndrome.
Interventions
DRUGSyB C-1101
SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle. The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7). From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
Sponsors
SymBio Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must satisfy the following conditions listed below. 1. Patients enrolled in the study 2012002 of SyB C-1101 in Patients With Myelodysplastic Syndrome. 2. Patients who were not judged as disease progression\* nor progressive disease/relapse\*\* at the end of the cycle 6 in the study 2012002. \* hematologic remission according to IWG 2006 criteria \*\* hematologic improvement according to IWG 2006 criteria 3. Patients who met the continuation criteria\*\*\* after Cycle 6 week 3 (Day 22±3) in the study 2012002. \*\*\*defined in the study 2012002 protocol 4.5 Criteria for Transition to the Next Cycle 4. Patients who can be expected to survive at least three months or longer. 5. Patients who have score of 0 to 2 in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS). 6. Patients with adequate function in major organs (heart, lungs, liver, kidneys, etc.). * Aspartate aminotransferase (AST): no more than 3.0 times the upper boundary of the reference range at each institution * Alanine aminotransferase (ALT): no more than 3.0 times the upper boundary of the reference range at each institution * Total bilirubin: no more than 1.5 times the upper boundary of the reference range at each institution * Serum creatinine: no more than 1.5 times the upper boundary of the reference range at each institution * ECG: no abnormal findings requiring treatment * Echocardiography: no abnormal findings requiring treatment 7. Patients who personally signed an informed consent document for participation in this study.
Exclusion criteria
Patients who satisfy any of the following conditions after Cycle 6 week 3 (Day 22±3) in the study 2012002 will not be enrolled in the study. 1. Patients with anemia caused by factors other than MDS(hemolytic anemia, gastrointestinal hemorrhage, etc.). 2. Patients with obvious infectious diseases (including viral infections). 3. Patients with serious complications (liver failure, renal failure, etc.). 4. Patients with a complication of serious heart disease (myocardial infarction, ischemic heart disease, etc.) 5. Patients with a serious gastrointestinal condition (severe or significant nausea/vomiting, diarrhea, etc.) 6. Patients with serious bleeding tendencies (disseminated intravascular coagulation (DIC), internal hemorrhage, etc.). 7. Ascites or pleural fluid requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of \< 130 mEq/L). 8. Patients with known allergy to polyethylene glycol or gelatin capsules. 9. Patients with an addiction to a legal or illegal drug, or with alcohol dependency. 10. Patients who are nursing, pregnant or may become pregnant, or lactating mothers. 11. Patients who have not consented to the following contraceptive measures. Patients will avoid sexual intercourse with sexual partners or should use the following contraceptive methods in these time periods: for male patients during the administration period of the trial and for six months after the end of administration; female patients during the administration period of the trial and until a second menstrual period is confirmed after the end of administration (or in the case of female patients with no menstrual period, for two months after the end of administration). 1) Male patients: Patients will always use a condom. For effective contraception, it is recommended that the female partner also use the contraceptive methods for female patients. 2) Female patients: Female patients who may become pregnant should use one or more types of the following contraceptive methods. In addition, the male partner will always use a condom. * Oral contraceptive (birth control pills) * Intrauterine device (IUD) * Tubal ligation 12. Other patients judged to be unsuitable by an investigator or sub-investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | Up to 3 years | Total number affected by any adverse events (details are presented in adverse event section) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total Efficacy in Hematologic Remission (IWG2006 Criteria) | Up to 3 years | SD (stable disease): according to International Working Group 2006 response criteria for myelodysplastic syndrome, SD was defined as a failure to achieve complete remission or partial remission, but no evidence of progression for \> 8 weeks. |
| Total Efficacy in Hematologic Improvement Ratio According to IWG 2006 Criteria. | Up to 3 years | NCA (not considered assessable): no evidence of HI-E (hematologic improvement-erythroid), HI-P (hematologic improvement-platelet), HI-N (hematologic improvement-neutorophil), progressive disease, or relapse. |
| Cytogenetic Response Ratio According to IWG 2006 Criteria | Up to 3 years | NCA (not considered assessable): no cytogenetic response |
| Overall Survival | Up to 3 years | Survived |
| Changes in Clinical Laboratory Test Results | Up to 3 years | Clinically significant changes |
Countries
Japan
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| SyB C-1101 SyB C-1101 （rigosertib sodium）:
Following Cycle 6 of Study 2012002, the treatment in this study was initiated. One cycle was defined as a 21-day cycle; 14-day oral administration of SyB C-1101 twice daily (Days 1 to 14) followed by a 1-week observation period (Days 15 to 21). The starting dose of SyB C-1101 in this study (Cycle 7) was the same as that was determined for the next cycle in Cycle 6 of Study 2012002. | 1 |
| Total | 1 |
Baseline characteristics
| Characteristic | SyB C-1101 |
|---|---|
| Age, Customized 50-59 years | 1 participants |
| Age, Customized 60-69 years | 0 participants |
| Age, Customized 70-79 years | 0 participants |
| Age, Customized 80-years | 0 participants |
| Gender Female | 0 Participants |
| Gender Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 1 / 1 |
| serious Total, serious adverse events | 0 / 1 |
Outcome results
Primary
Adverse Events
Total number affected by any adverse events (details are presented in adverse event section)
Time frame: Up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB C-1101 | Adverse Events | 1 participants |
Secondary
Changes in Clinical Laboratory Test Results
Clinically significant changes
Time frame: Up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB C-1101 | Changes in Clinical Laboratory Test Results | 0 participants |
Secondary
Cytogenetic Response Ratio According to IWG 2006 Criteria
NCA (not considered assessable): no cytogenetic response
Time frame: Up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB C-1101 | Cytogenetic Response Ratio According to IWG 2006 Criteria | 1 participants |
Secondary
Overall Survival
Survived
Time frame: Up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB C-1101 | Overall Survival | 1 participants |
Secondary
Total Efficacy in Hematologic Improvement Ratio According to IWG 2006 Criteria.
NCA (not considered assessable): no evidence of HI-E (hematologic improvement-erythroid), HI-P (hematologic improvement-platelet), HI-N (hematologic improvement-neutorophil), progressive disease, or relapse.
Time frame: Up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB C-1101 | Total Efficacy in Hematologic Improvement Ratio According to IWG 2006 Criteria. | 1 participants |
Secondary
Total Efficacy in Hematologic Remission (IWG2006 Criteria)
SD (stable disease): according to International Working Group 2006 response criteria for myelodysplastic syndrome, SD was defined as a failure to achieve complete remission or partial remission, but no evidence of progression for \> 8 weeks.
Time frame: Up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SyB C-1101 | Total Efficacy in Hematologic Remission (IWG2006 Criteria) | 1 participants |